Yekaterina V. Fatakhova

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Over the past four decades there have been minimal improvements in outcomes for patients with osteosarcoma. New targets and novel therapies are needed to improve outcomes for these patients. We sought to evaluate the prevalence and clinical significance of the newest immune checkpoint, HHLA2, in osteosarcoma. HHLA2 protein expression was evaluated in(More)
  • 1